Results for "Clinical Trials"
Pharmaceutical Chemistry
Pharmaceutical chemistry is the scientific discipline focused on designing, synthesizing, and developing pharmaceutical drugs by analyzing chemical structures and their biological interactions to create effective therapies.
Health & MedicineTCR Therapy
**TCR (T-Cell Receptor) therapy** is a type of immunotherapy that uses genetically modified T-cells to recognize and destroy cancer cells, offering a promising treatment option for various types of cancer. ## Overview **TCR therapy** is a cutting-edge approach in cancer treatment that leverages the body's immune system to fight cancer cells. This innovative therapy involves extracting T-cells from a patient's blood, genetically modifying them to recognize specific cancer antigens, and then reinfusing them into the body. The modified T-cells, also known as **TCR-engineered T-cells**, can recognize and target cancer cells, leading to their destruction. This targeted approach aims to minimize harm to healthy cells and reduce the side effects associated with traditional cancer treatments. **TCR therapy** has shown significant promise in treating various types of cancer, including melanoma, lung cancer, and lymphoma. The therapy works by exploiting the unique characteristics of cancer cells, which often display specific antigens on their surface. By modifying T-cells to recognize these antigens, **TCR therapy** enables the immune system to selectively target and eliminate cancer cells. The development of **TCR therapy** has been a collaborative effort between researchers, scientists, and clinicians. This innovative approach has the potential to revolutionize cancer treatment, offering new hope to patients with limited treatment options. ## History/Background The concept of **TCR therapy** dates back to the 1990s, when researchers first began exploring the use of genetically modified T-cells to treat cancer. However, it wasn't until the early 2000s that the first clinical trials were conducted. Since then, numerous studies have been conducted to evaluate the safety and efficacy of **TCR therapy** in various cancer types. Key milestones in the development of **TCR therapy** include: * 1990s: Researchers first explore the use of genetically modified T-cells to treat cancer. * 2000s: First clinical trials of **TCR therapy** are conducted. * 2010s: **TCR therapy** shows promising results in treating various types of cancer, including melanoma and lung cancer. * 2020s: **TCR therapy** continues to evolve, with new clinical trials and studies investigating its use in combination with other cancer treatments. ## Key Information **TCR therapy** has several key characteristics that make it an attractive treatment option: * **Targeted approach**: **TCR therapy** selectively targets cancer cells, minimizing harm to healthy cells. * **Personalized medicine**: **TCR therapy** is tailored to each patient's specific cancer type and characteristics. * **Potential for long-term response**: **TCR therapy** has been shown to induce long-term responses in some patients. * **Combination therapy**: **TCR therapy** can be used in combination with other cancer treatments, such as chemotherapy and radiation therapy. However, **TCR therapy** also has some limitations and potential side effects, including: * **Immune-related adverse events**: Patients may experience immune-related side effects, such as skin rash or diarrhea. * **T-cell exhaustion**: Modified T-cells may become exhausted and less effective over time. * **Tumor heterogeneity**: Cancer cells may develop resistance to **TCR therapy** through genetic mutations. ## Significance **TCR therapy** has the potential to revolutionize cancer treatment, offering a new approach to targeting and eliminating cancer cells. This innovative therapy has shown significant promise in treating various types of cancer, and its use in combination with other cancer treatments may enhance its effectiveness. The significance of **TCR therapy** extends beyond its potential to improve cancer treatment outcomes. It also highlights the importance of: * **Personalized medicine**: **TCR therapy** demonstrates the potential of personalized medicine in treating cancer. * **Immunotherapy**: **TCR therapy** showcases the power of immunotherapy in harnessing the body's immune system to fight cancer. * **Collaborative research**: The development of **TCR therapy** has been a collaborative effort between researchers, scientists, and clinicians. INFOBOX: - Name: T-Cell Receptor (TCR) Therapy - Type: Immunotherapy - Date: 1990s (concept development), 2000s (first clinical trials) - Location: Various research institutions and hospitals worldwide - Known For: Promising treatment option for various types of cancer TAGS: Immunotherapy, Cancer Treatment, T-Cell Receptor, Personalized Medicine, Immunotherapy, Cancer Research, Clinical Trials, Oncology.
Health & MedicineConditions Encyclopedia Entry 1780609884
** This encyclopedia entry is about **Mitochondrial Myopathies**, a group of rare genetic disorders affecting the mitochondria, the energy-producing structures within cells. **CONTENT** ### Overview Mitochondrial Myopathies (MM) are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. These disorders are caused by mutations in the mitochondrial DNA, which are responsible for producing energy for the cell. Mitochondrial Myopathies can affect various parts of the body, including the muscles, brain, and other organs. The symptoms of MM can vary widely, but often include muscle weakness, fatigue, and other systemic problems. Mitochondrial Myopathies are a complex and heterogeneous group of disorders, with over 150 different mutations identified in the mitochondrial DNA. The most common forms of MM include Kearns-Sayre Syndrome (KSS), Myoclonic Epilepsy with Ragged-Red Fibers (MERRF), and Chronic Progressive External Ophthalmoplegia (CPEO). Each of these forms has distinct clinical features and prognoses. The diagnosis of Mitochondrial Myopathies is often challenging, as the symptoms can be nonspecific and overlap with other conditions. A diagnosis is typically made through a combination of clinical evaluation, genetic testing, and muscle biopsy. ### History/Background The first reported case of Mitochondrial Myopathy was in 1957, when a 12-year-old boy was described with a rare condition characterized by progressive external ophthalmoplegia and muscle weakness. However, it wasn't until the 1960s and 1970s that the mitochondrial DNA was identified as the source of the mutations causing these disorders. In the 1980s, the first molecular genetic studies were conducted on Mitochondrial Myopathies, leading to the identification of several key mutations. The development of genetic testing and muscle biopsy techniques has greatly improved the diagnosis and management of MM. ### Key Information **Key Facts:** - **Prevalence:** Mitochondrial Myopathies are rare, affecting approximately 1 in 5,000 to 1 in 10,000 people. - **Inheritance:** MM can be inherited in an autosomal dominant, autosomal recessive, or mitochondrial pattern. - **Symptoms:** Muscle weakness, fatigue, seizures, vision problems, and other systemic symptoms. - **Prognosis:** The prognosis varies depending on the specific form of MM, but most patients experience a gradual decline in function over time. **Key Achievements:** - **Genetic testing:** The development of genetic testing has greatly improved the diagnosis of MM. - **Muscle biopsy:** Muscle biopsy has become a crucial tool in the diagnosis and management of MM. - **Clinical trials:** Several clinical trials have been conducted to investigate the effectiveness of various treatments for MM. ### Significance Mitochondrial Myopathies are a significant public health concern, as they can have a profound impact on the quality of life of affected individuals and their families. The diagnosis and management of MM require a multidisciplinary approach, involving geneticists, neurologists, and other specialists. The study of Mitochondrial Myopathies has also led to a greater understanding of the role of mitochondria in human disease and has implications for the treatment of other conditions, such as neurodegenerative diseases and cancer. **INFOBOX** - **Name:** Mitochondrial Myopathies - **Type:** Rare genetic disorder - **Date:** 1957 (first reported case) - **Location:** Worldwide - **Known For:** Rare genetic disorders affecting the mitochondria **TAGS:** Mitochondrial Myopathies, Rare Genetic Disorders, Mitochondrial DNA, Muscle Weakness, Fatigue, Seizures, Vision Problems, Genetic Testing, Muscle Biopsy, Clinical Trials, Multidisciplinary Approach.